New drug approvals for 2022: Synthesis and clinical applications.
chemical synthesis
clinical applications
fragment-based drug discovery
mechanism of action
new drugs
Journal
Medicinal research reviews
ISSN: 1098-1128
Titre abrégé: Med Res Rev
Pays: United States
ID NLM: 8103150
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
13
04
2023
received:
04
01
2023
accepted:
08
05
2023
pubmed:
22
5
2023
medline:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
The U.S. Food and Drug Administration has approved a total of 37 new drugs in 2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 chemical entities, including 17 small molecule drugs, 1 radiotherapy, and 2 diagnostic agents, provide privileged scaffolds, breakthrough clinical benefits, and a new mechanism of action for the discovery of more potent clinical candidates. The structure-based drug development with clear targets and fragment-based drug development with privileged scaffolds have always been the important modules in the field of drug discovery, which could easily bypass the patent protection and bring about improved biological activity. Therefore, we summarized the relevant valuable information about clinical application, mechanism of action, and chemical synthesis of 17 newly approved small molecule drugs in 2022. We hope this timely and comprehensive review could bring about creative and elegant inspiration on the synthetic methodologies and mechanism of action for the discovery of new drugs with novel chemical scaffolds and extended clinical indications.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2352-2391Subventions
Organisme : National Natural Science Foundation of China
ID : U21A20416
Organisme : National Natural Science Foundation of China
ID : 82020108030
Organisme : Scientific and Technological Project of Henan Province
ID : 232102311165
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Urquhart L. FDA new drug approvals in Q1 2022. Nat Rev Drug Discov. 2022;21:329.
Urquhart L. FDA new drug approvals in Q2 2022. Nat Rev Drug Discov. 2022;21:550.
Brown A. FDA new drug approvals in Q3 2022. Nat Rev Drug Discov. 2022;21:788.
Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19:79-84.
Mullard A. 2020 FDA drug approvals. Nat Rev Drug Discov. 2021;20:85-90.
Mullard A. 2021 FDA approvals. Nat Rev Drug Discov. 2022;21:83-88.
Vanreppelen G, Nysten J, Baldewijns S, Sillen M, Donders G, Van Dijck P. Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis. Trends Pharmacol Sci. 2023;44:64-65.
Schwartzberg LS, Bhat G, Peguero J, et al. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. Oncologist. 2020;25:1233-1241.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386:1793-1803.
Dauvilliers Y, Zammit G, Fietze I, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol. 2020;87:347-356.
Hanna E, Pon K. Updates on botulinum neurotoxins in dermatology. Am J Clin Dermatol. 2020;21:157-162.
Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84:1059-1067.
Blair HA. Spesolimab: first approval. Drugs. 2022;82:1681-1686.
Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86:148-157.
Dolgin E. Cancer drug approvals and setbacks in 2022. Nature Cancer. 2022;3:1406-1408.
Stäglich R, Kemnitzer TW, Harder MC, et al. Portable hyperpolarized Xe-129 apparatus with long-time stable polarization mediated by adaptable Rb vapor density. J Phys Chem A. 2022;126:2578-2589.
Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32:757-765.
Dhillon S. Tebentafusp: first approval. Drugs. 2022;82:703-710.
Ou-Yang S, Lu J, Kong X, Liang Z, Luo C, Jiang H. Computational drug discovery. Acta Pharmacol Sin. 2012;33:1131-1140.
Gentile F, Yaacoub JC, Gleave J, et al. Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking. Nat Protoc. 2022;17:672-697.
Bianco G, Goodsell DS, Forli S. Selective and effective: current progress in computational structure-based drug discovery of targeted covalent inhibitors. Trends Pharmacol Sci. 2020;41:1038-1049.
Wang ZZ, Shi XX, Huang GY, Hao GF, Yang GF. Fragment-based drug design facilitates selective kinase inhibitor discovery. Trends Pharmacol Sci. 2021;42:551-565.
Baker M. Fragment-based lead discovery grows up. Nat Rev Drug Discov. 2013;12:5-7.
Sheng C, Zhang W. Fragment informatics and computational fragment-based drug design: an overview and update. Med Res Rev. 2013;33:554-598.
Yuan S, Yu B, Liu HM. New drug approvals for 2019: synthesis and clinical applications. Eur J Med Chem. 2020;205:112667.
Yuan S, Luo YQ, Zuo JH, Liu H, Li F, Yu B. New drug approvals for 2020: synthesis and clinical applications. Eur J Med Chem. 2021;215:113284.
Yuan S, Wang DS, Liu H, et al. New drug approvals for 2021: synthesis and clinical applications. Eur J Med Chem. 2023;245:114898.
Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17:15-21.
Sobel JD, Nyirjesy P. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol. 2021;16:1453-1461.
Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59:153-161.
Okano JT, Sharp K, Valdano E, Palk L, Blower S. HIV transmission and source-sink dynamics in sub-saharan Africa. Lancet HIV. 2020;7:209-214.
Bandera A, Gori A, Clerici M, Sironi M. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol. 2019;48:24-32.
Paik J. Lenacapavir: first approval. Drugs. 2022;82:1499-1504.
Orkin C. Lenacapavir in first-line therapy. Lancet HIV. 2023;10:2-3.
Marrazzo J. Lenacapavir for HIV-1: potential promise of a long-acting antiretroviral drug. N Engl J Med. 2022;386:1848-1849.
Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584:614-618.
Rosati D, Bruno M, Jaeger M, ten Oever J, Netea MG. Recurrent vulvovaginal candidiasis: an immunological perspective. Microorganisms. 2020;8:144.
Zhu T, Chen X, Li C, et al. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. Eur J Med Chem. 2021;221:113524.
Hoy SM. Oteseconazole: first approval. Drugs. 2022;82:1017-1023.
Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol. 2022;61:1431-1441.
Brand SR, Sobel JD, Nyirjesy P, Ghannoum MA, Schotzinger RJ, Degenhardt TP. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73:1518-1524.
Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2014;24:3455-3458.
Moodley Y, Brunelli A, Ghirotto S, et al. Helicobacter pylori's historical journey through Siberia and the Americas. Proc Natl Acad Sci USA. 2021;118:2015523118.
Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446-4456.
Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75:439-443.
Yang X, Li Y, Sun Y, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018;63:302-311.
Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2018;67:1033-1041.
Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology. 2021;238:2693-2708.
Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31-39.
Kay-Stacey M, Attarian H. Advances in the management of chronic insomnia. BMJ. 2016;354:2123.
Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABA(A) receptor. Nature. 2018;559:67-72.
Kasaragod VB, Mortensen M, Hardwick SW, et al. Mechanisms of inhibition and activation of extrasynaptic αβ GABAA receptors. Nature. 2022;602:529-533.
Roecker AJ, Cox CD, Coleman PJ. Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia. J Med Chem. 2016;59:504-530.
Markham A. Daridorexant: first approval. Drugs. 2022;82:601-607.
Zammit G, Dauvilliers Y, Pain S, Sebök Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94:2222-2232.
Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21:125-139.
Rappas M, Ali AAE, Bennett KA, et al. Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis. J Med Chem. 2020;63:1528-1543.
Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
Sun Y, Li X, Bedlack R. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2023;23:1-7.
Johnson SA, Fang T, De Marchi F, et al. Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents. Drugs. 2022;82:1367-1388.
Paganoni S, Watkins C, Cawson M, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022;66:136-141.
Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919-930.
Huang Y, Lin L, Yang Y, et al. Effect of tauroursodeoxycholic acid on inflammation after ocular alkali burn. Int J Mol Sci. 2022;23:11717.
Uppal SK, Chat VS, Kearns DG, Wu JJ. Abrocitinib for atopic dermatitis. The Lancet. 2021;397:195-196.
Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813-822.
Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110-2119.
Ständer S. Atopic dermatitis. N Engl J Med. 2021;384:1136-1143.
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18:301-304.
Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81:2149-2157.
Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:1-7.
Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101-1112.
Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N-cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutylpropane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61:1130-1152.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301-1315.
Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80:341-352.
Liu C, Lin J, Langevine C, et al. Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2. J Med Chem. 2021;64:677-694.
Hoy SM. Deucravacitinib: first approval. Drugs. 2022;82:1671-1679.
Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149:2010-2020.
Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29-39.
Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;62:8973-8995.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.
Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14:801-814.
Keam SJ. Tapinarof cream 1%: first approval. Drugs. 2022;82:1221-1228.
Assaf J, Sarkis J, Tomb R. Tapinarof and the future of topical treatments in plaque psoriasis. J Am Acad Dermatol. 2021;84:283-284.
Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinar of cream for plaque psoriasis. N Engl J Med. 2021;385:2219-2229.
Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617-621.
Sharma P, Moore K, Ganger D, Grewal P, Brown RS. Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation. Liver Transpl. 2020;26:1328-1336.
Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020;370:2687.
Chen L, Jung HJ, Datta A, et al. Systems biology of the vasopressin V2 receptor: new tools for discovery of molecular actions of a GPCR. Annu Rev Pharmacol Toxicol. 2022;62:595-616.
Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine. 2018;97:0431.
Goletti D, Cantini F. Baricitinib therapy in Covid-19 pneumonia-an unmet need fulfilled. N Engl J Med. 2021;384:867-869.
Belcher JM, Parada XV, Simonetto DA, et al. Terlipressin and the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward. Am J Kidney Dis. 2022;79:737-745.
Glavaš M, Gitlin-Domagalska A, Dębowski D, Ptaszyńska N, Łęgowska A, Rolka K. Vasopressin and its analogues: from natural hormones to multitasking peptides. Int J Mol Sci. 2022;23:3068.
Yawno T, Miller SL, Bennet L, et al. Ganaxolone: a new treatment for neonatal seizures. Front Cell Neurosci. 2017;11:246.
Tower-Rader A, Ramchand J, Nissen SE, Desai MY. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Expert Opin Invest Drugs. 2020;29:1171-1178.
Costa FF. Mitapivat for treatment of pyruvate kinase deficiency. Lancet Haematol. 2022;9:708-709.
Leonard H, Downs J, Benke TA, Swanson L, Olson H, Demarest S. CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol. 2022;21:563-576.
Ragavendran JV, Sriram D, Kotapati S, Stables J, Yogeeswari P. Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach. Eur J Med Chem. 2008;43:2650-2655.
Lamb YN. Ganaxolone: first approval. Drugs. 2022;82:933-940.
Miller SL, Bennet L, Sutherland AE, et al. Ganaxolone versus phenobarbital for neonatal seizure management. Ann Neurol. 2022;92:1066-1079.
Knight EMP, Amin S, Bahi-Buisson N, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21:417-427.
Witkin JM, Lippa A, Smith JL, et al. The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacol Biochem Behav. 2022;213:173321.
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242-255.
Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019;9:878.
Roman BI, Verhasselt S, Stevens CV. Medicinal chemistry and use of myosin II inhibitor (S)-blebbistatin and its derivatives. J Med Chem. 2018;61:9410-9428.
Keam SJ. Mavacamten: first approval. Drugs. 2022;82:1127-1135.
Quintana E, Bajona P, Myers PO. Mavacamten for hypertrophic obstructive cardiomyopathy. Lancet. 2021;397:369.
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759-769.
Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012;45:598-609.
Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev. 2007;21:217-231.
Al-Samkari H, van Beers EJ. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Ther Adv Hematol. 2021;12:204062072110660.
Rab MAE, Van Oirschot BA, Kosinski PA, et al. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2020;106:238-249.
Grace RF, Rose C, Layton DM, et al. Safety and efficacy of mitapivat in pyruvate kinase deficiency. N Engl J Med. 2019;381:933-944.
Sizemore JP, Guo L, Mirmehrabi M, et al. Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. 2019; WO2019104134A1.
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32:1101-1110.
Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986-4997.
Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet Haematology. 2023;10:46-58.
Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 2022;15:671-684.
Hu J, Xia X, Wang P, et al. Predicting Kirsten rat sarcoma virus gene mutation status in patients with colorectal cancer by radiomics models based on multiphasic CT. Front Oncol. 2022;12:848798.
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543-550.
Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 2019;9:871-879.
Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.
Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387:120-131.
Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16:1321-1332.
Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382-2393.
Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer. J Med Chem. 2020;63:6679-6693.
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95-111.
Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318-332.
Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684-2694.
Syed YY. Futibatinib: first approval. Drugs. 2022;82:1737-1743.
Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Invest Drugs. 2021;30:317-324.
Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discovery. 2022;12:402-415.
Abe Y, Emori K. Application of a statistical approach to process development of futibatinib by employing quality-by-design principles. Part 1: identification of critical process parameters for impurities. Org Process Res Dev. 2022;26:43-55.
Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14:49.
Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18:645-661.
Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580-1589.
Salifu EY, Agoni C, Soliman MES. Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy. Inform Med Unlocked. 2022;28:100829.
Fuente MI, Colman H, Rosenthal M, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol. 2022;25:146-156.
Caravella JA, Lin J, Diebold RB, et al. Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor. J Med Chem. 2020;63:1612-1623.
Garmezy B, Schaefer JK, Mercer J, Talpaz M. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Rev. 2021;45:100691.
Pandey G, Kuykendall AT, Reuther GW. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022;12:13.
Lamb YN. Pacritinib: first approval. Drugs. 2022;82:831-838.
Patel AA, Odenike O. The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib. Curr Hematol Malig Rep. 2020;15:409-418.
Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652-659.
William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem. 2011;54:4638-4658.
Inoue K, Inoue J, Kunimatsu-Sanuki S, et al. Short-term efficacy and safety of omidenepag isopropyl in patients with normal-tension glaucoma. Clin Ophthalmol. 2020;14:2943-2949.
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901-1911.
Konya V, Marsche G, Schuligoi R, Heinemann A. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther. 2013;138:485-502.
Duggan S. Omidenepag isopropyl ophthalmic solution 0.002%: first global approval. Drugs. 2018;78:1925-1929.
Nakakura S, Kanamori A, Fukuma Y, Wakabayashi S, Nagata Y, Adachi M. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study. BMJ Open. 2021;11:040301.
Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2020;220:53-63.
Iwamura R, Tanaka M, Okanari E, et al. Identification of a selective, non-prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl. J Med Chem. 2018;61:6869-6891.
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41-58.
Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021;42:255-267.
Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5:113.
Nensa F, Demircioglu A, Rischpler C. Artificial intelligence in nuclear medicine. J Nucl Med. 2019;60:29-37.
Hong B, Luo T, Lei X. Late-stage diversification of natural products. ACS Cent Sci. 2020;6:622-635.
Pennington LD, Muegge I. Holistic drug design for multiparameter optimization in modern small molecule drug discovery. Bioorg Med Chem Lett. 2021;41:128003.
Liu L, Jockers R. Structure-based virtual screening accelerates GPCR drug discovery. Trends Pharmacol Sci. 2020;41:382-384.
Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200-216.